Skip to content
Screener

Innovate VATE Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$421.6MBeat by $169.9M
EPS$0.71Beat by $2.89
Revenue estimate$251.7M
EPS estimate-$2.18
We continue to make progress across our key strategic priorities and believe the momentum we saw during the second quarter reinforces the value and potential of our portfolio. DBM Global delivered exceptional results, supported by strong execution, robust backlog growth, and favorable end-market demand. At MediBeacon, we continue to focus on commercialization efforts, reimbursement initiatives, and global regulatory activities, while R2 exited the quarter with strong demand and an expanding international presence. We remain focused on strengthening our balance sheet, advancing growth initiatives and creating long-term value for our shareholders.
Paul Voigt

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$251.7M
EPS estimate-$2.18

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$104.5M+47.6%
Enterprise value$1.37B+13.1%
P/S0.1×0.0×

FAQ

When did Innovate report Q2 2026 earnings?
Innovate (VATE) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Innovate's Q2 2026 revenue and EPS?
Innovate reported revenue of $421.6M and eps of $0.71 for Q2 2026.
Did Innovate beat estimates in Q2 2026?
Revenue beat the consensus estimate of $251.7M by $169.9M. EPS beat the consensus estimate of $-2.18 by $2.89.
How did Innovate's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 74.2% from $242.0M a year earlier.
Where can I find Innovate's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001006837-26-000053) and the 10-Q periodic report (0001006837-26-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.